Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ying Zhuo

Hematology & Oncology Kennewick, WA Medical Doctor

NPI 1043491293 CMS profile 2551

7360 W Deschutes Ave, Kennewick, WA 99336

Open in the dashboard

General payments

$43,039

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,844,332 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ying Zhuo of Kennewick, WA is reported in the CMS Open Payments database as having received $43,039 across 85 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,844,332 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,075 6
2024 General $3,752 5
2023 General $9,182 8
2022 General $9,125 15
2021 General $5,706 6
2020 General $1,636 10
2019 General $7,562 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ying Zhuo
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Ying Zhuo were reported at $6,075. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Ying Zhuo Hematology & Oncology median Middle half National median
2019 $7,562 $529 $121–$2,516 $163
2020 $1,636 $339 $82–$2,213 $114
2021 $5,706 $263 $49–$1,965 $132
2022 $9,125 $416 $103–$2,395 $149
2023 $9,182 $542 $125–$2,646 $160
2024 $3,752 $692 $141–$3,008 $164
2025 $6,075 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $15,875 21 payments
  2. Pfizer Inc. $7,672 14 payments
  3. Karyopharm Therapeutics Inc. $6,520 2 payments
  4. Daiichi Sankyo Inc. $5,368 6 payments
  5. Genentech USA, Inc. $1,825 4 payments
  6. Janssen Scientific Affairs, LLC $1,776 3 payments
  7. Incyte Corporation $1,650 1 payment
  8. Genentech, Inc. $1,557 3 payments
  9. Foundation Medicine, Inc. $148 2 payments
  10. E.R. Squibb & Sons, L.L.C. $121 7 payments
  11. Other $528 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $37,136 21 payments
  2. Honoraria $2,950 2 payments
  3. Food and Beverage $1,860 56 payments
  4. Travel and Lodging $1,064 4 payments
  5. Education $29 2 payments
Products named General payments · program years 2019–2025
  1. CALQUENCE $7,371 12 payments
  2. XPOVIO $6,520 2 payments
  3. IBRANCE $5,994 9 payments
  4. ENHERTU $5,368 6 payments
  5. LYNPARZA $4,806 3 payments
  6. VENCLEXTA $3,280 2 payments
  7. LORBRENA $1,666 4 payments
  8. FOUNDATIONONE CDX $148 2 payments
  9. FOUNDATIONONE $148 2 payments
  10. FOUNDATIONONE HEME $148 2 payments
  11. Other $1,469 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,940

Median for Hematology-Oncology: 604

Drug cost

$2,348,748

Median for Hematology-Oncology: $1,306,514

Branded share of claims

22.5%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Verzenio Abemaciclib Brand 30 $571,263
Ibrance Palbociclib Brand 30 $470,306
Lenalidomide Generic 24 $365,141
Pomalyst Pomalidomide Brand 11 $251,900
Revlimid Lenalidomide Brand 11 $205,733
Venclexta Venetoclax Brand 14 $174,654
Tavalisse Fostamatinib Disodium Brand 12 $162,212
Eliquis Apixaban Brand 63 $61,633
Creon Lipase/Protease/Amylase Brand 17 $29,631
Xarelto Rivaroxaban Brand 21 $14,688

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$141,752

Medicare's payments for the services billed

Medicare patients

516

Average age 74

Services billed

3,629

354 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Cancer 66%
Arthritis 42%
Diabetes 30%
Chronic kidney disease 28%
Depression 21%
Ischemic heart disease 20%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VENCLEXTA
  • Genentech USA, Inc. $1,765
$1,765 14 —
ENHERTU
  • Daiichi Sankyo Inc. $95
$95 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $25
$25 — —
GAZYVA
  • Genentech, Inc. $5
$5 — —
LUNSUMIO
  • Genentech, Inc. $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record